DNGinkgo Bioworks Holdings, Inc. DNA · NYSE
$9.81 +0.98% (+$0.10)
- Market cap
- $654.9M
- Enterprise value
- $974.5M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 5.9x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -31.6%
- Gross margin
- 80.1%
- Net margin
- -260.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.80
- Free float
- 72.9%
About the company
Ginkgo Bioworks Holdings, Inc. (DNA) is a biotechnology company focused on synthetic biology and engineering microorganisms. The company uses advanced technologies and biological systems to create new organisms and biological functions for various applications. Ginkgo Bioworks specializes in genetic modification and design of microorganisms, enabling the production of novel drugs, biochemical substances, industrial products, and other biologically-based technologies. The company collaborates with various industries and pharmaceutical companies on the development of new products and innovations that can have a positive impact on the environment and human health. Ginkgo Bioworks Holdings, Inc. (DNA) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focused on innovation and the development of biological technologies with the potential for broader societal impact.
Sector
Healthcare
Industry
Biotechnology
CEO
Jason Kelly
Employees
485
Headquarters
Boston
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number